CTLA4 and non-small cell lung carcinoma: Multiple checkpoint inhibitors have been FDA approved alone, in combination (anti-PD-(L)1/CTLA-4) or with chemotherapy for NSCLC in the locally-advanced or metastatic setting including nivolumab, pembrolizumab, durvalumab, atezolizumab, ipilimumab, and tremelimumab (1–7).